In neoadjuvant immunotherapy recipients (Supplementary Table 5), high expression of DYNLL1-AS1 in tumors displayed attenuated CD8+ T cell infiltration, amplified PD-L1+ TAMs densities (Figure 7A-D), and diminished pathological response rates (tumor regression grade 3: 23.1% vs 60%, Supplementary Table 6). Here, DYNLL1 is linked to neoplasm.